Core Viewpoint - Cencora is acquiring the retina business of EyeSouth Partners for $1.1 billion, which will enhance its eye care unit [1] Company Summary - Cencora is a drug distributor that is expanding its operations in the eye care sector through this acquisition [1] - EyeSouth Partners is an eye care network whose retina business is being sold to Cencora [1] Financial Summary - The acquisition deal is valued at $1.1 billion, indicating a significant investment by Cencora to strengthen its position in the eye care market [1]

Company Overview - Abbott Laboratories, founded in 1888, is a significant player in medical devices and healthcare products, with a diverse product line including diabetes management, cardiovascular health, and nutrition [2][7] - The company is particularly noted for its FreeStyle Libre product, a leader in the continuous glucose monitoring (CGM) market, and its cardiovascular devices [1][7] Financial Performance - Abbott's recent financial results for 4Q25 showed total sales of $11.46 billion, a 4.4% year-over-year increase, but fell short of forecasts by $342.9 million [8] - The Medical Devices segment was the strongest performer, generating $5.675 billion in sales, reflecting a 12.3% year-over-year gain, while the nutrition segment experienced an 8.9% decline, landing at $1.94 billion [8] - Non-GAAP EPS was reported at $1.50, up nearly 12% from the previous year, exceeding estimates by a penny [9] Market Trends and Opportunities - UBS analysts highlight a growing longevity market, estimated at $5.3 trillion in 2023, projected to reach $8 trillion by 2030, with healthcare being a central focus [4][5] - Companies like Abbott are well-positioned to benefit from the aging population, particularly in the CGM and cardiovascular markets, which are expected to drive better health outcomes [10] Analyst Insights - UBS analyst Danielle Antalffy has a Buy rating on Abbott with a price target of $158, indicating a potential 47% upside, citing expected sales growth and resolution of litigation as key factors [10] - Wall Street consensus shows a Strong Buy rating for Abbott, with a favorable 14 to 1 split in recent reviews, suggesting a 28% one-year upside potential based on current trading price and average target [11] Competitive Landscape - Alcon, another company highlighted by UBS, specializes in eye care devices and has a market cap of $37.7 billion, with a strong global presence [11][12] - Alcon's revenue for 4Q25 grew 9% year-over-year to $2.7 billion, aligning with expectations, although it faced challenges from operational issues and US tariff policies [14] - UBS analyst Graham Doyle has a Buy rating on Alcon with a price target of $120.46, indicating a 61% upside potential, supported by anticipated product launches and positive EPS revisions [15]

Core Insights - Belize has launched the WHO SPECS 2030 initiative to enhance access to quality eye care for all citizens [1][3] Group 1: Initiative Overview - The WHO SPECS 2030 initiative aims to strengthen refractive error services through a structured approach across five areas [4] - Belize's implementation of the initiative focuses on three priorities: convening stakeholders, developing an integration plan with measurable targets, and establishing a monitoring and evaluation framework [5] Group 2: Stakeholder Involvement - The launch involved collaboration among various entities, including the Ministry of Health and Wellness, the Belize Council for the Visually Impaired, and the OneSight EssilorLuxottica Foundation [2][6] - The Belize Council for the Visually Impaired will lead coordination efforts to ensure commitments translate into actionable progress [9] Group 3: Monitoring and Evaluation - Progress will be assessed using defined indicators reported every three to five years, including school eye health program reach and availability of refractive services [7] - Belize will track effective cataract surgical coverage and refractive error coverage through population-based surveys and health system data [7] Group 4: Commitment to Eye Health - The initiative reflects Belize's commitment to universal health coverage and aims to prevent vision-related issues that hinder learning and quality of life [11] - The OneSight EssilorLuxottica Foundation supports the initiative by enhancing local capacity and improving service delivery models [6][12]

Core Viewpoint - Glaucoma Research Foundation (GRF) has partnered with Alcon to enhance glaucoma education for Spanish-speaking communities in the U.S. by releasing updated English and Spanish editions of the "Understanding and Living with Glaucoma" booklet and the first-ever Spanish audiobook [1][2][4] Group 1: Educational Resources - The "Understanding and Living with Glaucoma" booklet and audiobook serve as essential educational tools for patients and caregivers to understand glaucoma, treatment options, and the importance of ongoing care [2] - The new Spanish audiobook aims to remove barriers to understanding and provide accessible education for Spanish-speaking patients and families [3] Group 2: Partnership and Commitment - Alcon's support for the Spanish-language resources aligns with its mission to improve patient understanding and advance eye care [4] - The updated resources will be distributed to patients, caregivers, clinicians, and community organizations worldwide at the end of March, coinciding with World Glaucoma Week starting March 9 [4]

Core Insights - Bausch + Lomb Corporation has launched a new R&D "Teach-in" webinar series to provide insights on its differentiated product pipeline unveiled in November 2025 [1] Group 1 - The first event of the webinar series is scheduled for March 23, 2026, at 1:30 p.m. ET [1] - Yehia Hasha, the Executive Vice President of Research & Development and Chief Medical Officer, will lead the webinar [1]

Core Insights - Bausch + Lomb Corporation reported record financial results for Q4 2025, with revenue increasing by 7% to $1.405 billion and adjusted EBITDA rising by 27% to $330 million, contributing to a full-year revenue of $5.101 billion driven by a diversified portfolio [1][3] Financial Performance - The pharmaceutical segment experienced a 14% growth in Q4, while the Vision Care division, bolstered by an 8% increase in contact lens sales, generated $778 million in revenue for the quarter [1] - The dry eye treatment Miebo was a standout performer, with Q4 revenue soaring by 111% to $112 million, attributed to marketing investments and a strong sales force [2] - The surgical segment achieved a 20% growth in premium intraocular lenses, recovering from a previous product recall [2] Future Outlook - For 2026, the company aims to maintain its adjusted EBITDA margin at 23.5% through operational execution and financial discipline, despite competitive pressures in the IOL and contact lens markets [4] - Bausch + Lomb anticipates continued outperformance of its daily SiHy lenses in the global market and expects mid-single-digit sales growth for Xiidra as net pricing stabilizes [4] Company Overview - Bausch + Lomb operates in the eye health sector across multiple countries, including the US, Canada, and various international markets, with three main segments: Vision Care, Pharmaceuticals, and Surgical [5]

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1] Group 1: Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales to find attractive investment opportunities [3] - The Growth Score evaluates a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow to identify sustainable growth stocks [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of following market trends [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator that highlights stocks with strong value, growth potential, and positive momentum [6] Group 2: Zacks Rank and Stock Selection - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down their choices [8] - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while stocks with a 3 rank should also have high Style Scores to maximize upside potential [9] - Changes in a company's earnings outlook are crucial in stock selection, as stocks with lower ranks may still have high Style Scores but face downward price trends [10] Group 3: Company Spotlight - Alcon (ALC) - Alcon is a company specializing in eye care products, originally founded in 1945 and acquired by Novartis in 2011, currently holding a 2 (Buy) rating on the Zacks Rank with a VGM Score of B [11] - Alcon is particularly appealing to growth investors, with a Growth Style Score of B and a projected year-over-year earnings growth of 9.8% for the current fiscal year, alongside an upward revision in earnings estimates [12]

Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales at $151.7 million and a gross-to-net discount of 44% [3][20] - Total operating expenses for 2025 were $522.3 million, primarily due to commercial investments for the XDEMVY launch [20] - The company ended 2025 with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [20] Business Line Data and Key Metrics Changes - XDEMVY, the FDA-approved therapeutic for Demodex blepharitis, has helped over 500,000 patients since its launch and is expected to reach blockbuster status with sales potential exceeding $2 billion [3][4] - The company plans to expand its pipeline with two clinical-stage programs: TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, targeting one to two new programs per year [4][5] Market Data and Key Metrics Changes - The U.S. market for Demodex blepharitis is estimated to have 25 million affected individuals, with significant growth potential as awareness and treatment options expand [7][8] - Tarsus has achieved over 90% coverage across commercial Medicare and Medicaid, enhancing patient access [9] Company Strategy and Development Direction - Tarsus aims to create and lead new categories in eye care by identifying diseases with clear root causes and unmet needs, applying the successful development and commercial playbook established with XDEMVY [4][5] - The company is focused on disciplined growth, leveraging existing infrastructure while responsibly allocating capital to extend its long-term growth trajectory [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [7][34] - The company anticipates strong net product sales guidance for 2026 in the range of $670 million to $700 million, representing over 50% growth at the midpoint [21][22] Other Important Information - Tarsus is preparing for the Phase 2 trial of TP-04, expected to cost between $7 million and $10 million, and the Phase 2 trial of TP-05, estimated at $25 million to $30 million [25][72] - The company is also making progress with TP-03 for potential regulatory approval in Europe and Japan, with expectations for approval in China later this year [19] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $370 million-$400 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [31][32] Question: What is driving the increased conviction for the $2 billion peak sales target? - The increase is attributed to the broadening prescriber base and deeper engagement with top-tier prescribers, alongside continued flawless execution in commercial efforts [40][41] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [45][46] Question: What are the expected costs for the ocular rosacea and Lyme disease studies? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost $25 million to $30 million [72]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue reached $5.101 billion, up 5% [13][22] - Adjusted EBITDA for Q4 was $330 million, reflecting a 27% growth year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [12][20] - The full-year adjusted EBITDA was $891 million, with a margin of 17.5% [9][20] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [15] - Surgical segment revenue in Q4 was $249 million, a 3% increase, and full-year revenue was $894 million, up 4% [17] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [18] Market Data and Key Metrics Changes - The U.S. branded RX business in the pharma segment grew by 21% in Q4 and 13% for the full year [18] - Contact lens revenue growth was 8% in Q4 and 7% for the full year, with daily SiHy lenses up 17% in Q4 and 28% for the full year [16] - In China, contact lenses grew by 7% in Q4 and 8% for the full year [16] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline [5][6] - The strategy includes expanding the dry eye portfolio, with MIEBO expected to exceed $600 million in peak sales due to strong market access and execution [26][41] - The company aims to leverage its diversified product portfolio to drive sustained growth in the eye health market [11][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow faster than the market in 2026, with revenue guidance of $5.375 billion to $5.475 billion [22][23] - The company anticipates continued margin expansion and operating leverage, with adjusted EBITDA growth expected to outpace revenue growth [23][24] - Management highlighted the importance of execution and structural improvements in the P&L as key drivers of future performance [36][38] Other Important Information - The company reported an adjusted gross margin of 62.1% for Q4 and 61% for the full year [19] - Adjusted cash flow from operations was $152 million in Q4 and $381 million for the full year [20] - The adjusted tax rate for the full year was 10%, lower than previous guidance due to one-time adjustments [21] Q&A Session Summary Question: What are the key areas to execute for growth in 2026? - Management emphasized the importance of execution, structural improvements, and aligning the organization around clear priorities to achieve growth [36][38] Question: What lessons can be learned from MIEBO's success? - The success of MIEBO is attributed to a strong product with a favorable benefit-risk profile and effective execution strategies [40][43] Question: How does the company view the competitive landscape for 2026? - Management acknowledged competition but expressed confidence in their market position, particularly in the pharma segment with strong access and momentum [53][56]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved revenue of $1.405 billion, representing a 7% increase year-over-year, and full-year revenue reached $5.101 billion, up 5% [12][18] - Adjusted EBITDA for Q4 was $330 million, reflecting a 27% growth year-over-year, with an adjusted EBITDA margin of 23.5%, the highest since the company's IPO [11][18] - The adjusted gross margin for Q4 was 62.1%, with a full-year adjusted gross margin of 61% [17] Business Line Data and Key Metrics Changes - Vision Care segment revenue for Q4 was $778 million, up 5%, with full-year revenue of $2.923 billion, up 6% [13] - Surgical segment revenue in Q4 was $249 million, a 3% increase, with full-year revenue of $894 million, up 4% [15] - Pharma segment revenue for Q4 was $378 million, a 14% increase, with full-year revenue of $1.284 billion, up 6% [16] Market Data and Key Metrics Changes - The U.S. contact lens market grew by 11% in Q4, while international markets saw a 6% increase [14] - In China, contact lens revenue grew by 7% in Q4 and 8% for the full year [14] - The global dry eye market is expected to nearly double in the next four years, with significant growth attributed to MIEBO [27] Company Strategy and Development Direction - The company is focused on executing its three-year plan, emphasizing operational excellence and financial discipline [4][20] - The strategy includes expanding the dry eye portfolio and leveraging R&D to drive revenue growth [6][10] - The company aims to achieve revenue growth faster than the market across all segments in 2026 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong execution and a solid foundation for future success [39] - The company anticipates continued momentum in 2026, with expectations for revenue growth in the range of $5.375 billion to $5.475 billion [20] - Management highlighted the importance of disciplined execution and the impact of seasonality on revenue, particularly in the dry eye segment [68] Other Important Information - The company plans to maintain investments in R&D at 7.5%-8% of revenue, with adjusted EBITDA guidance for 2026 set between $1 billion and $1.05 billion [21][22] - The adjusted tax rate for 2026 is expected to be approximately 19% [22] Q&A Session Summary Question: What are the key areas to execute on for growth in 2026? - Management emphasized the importance of execution, structural improvements in the P&L, and aligning the organization around clear priorities [35][36] Question: What lessons can be learned from MIEBO's success? - Management noted that strong execution and a positive benefit-risk profile contributed to MIEBO's success, and these lessons will inform future pipeline strategies [40][41] Question: How will XIIDRA perform in 2026? - Management expects mid-single-digit sales growth for XIIDRA, balancing net price improvement with volume decline [77][80]